CervoMed Inc. financial data

Symbol
CRVO on Nasdaq
Location
Boston, MA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 13 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 16% % 71%
Return On Equity 130% % 2223%
Return On Assets -83% % -95%
Operating Margin -706% % -277%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 9,258,719 shares 6.4%
Common Stock, Shares, Outstanding 9,252,719 shares 6.3%
Entity Public Float $39,900,000 USD -56%
Common Stock, Value, Issued $9,252 USD 6.3%
Weighted Average Number of Shares Outstanding, Basic 9,041,760 shares 12%
Weighted Average Number of Shares Outstanding, Diluted 8,702,764 shares 131%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $4,006,510 USD -59%
Research and Development Expense $21,817,072 USD 16%
General and Administrative Expense $10,484,315 USD 14%
Operating Income (Loss) $28,294,877 USD -55%
Nonoperating Income (Expense) $1,328,510 USD -31%
Net Income (Loss) Attributable to Parent $26,966,367 USD -66%
Earnings Per Share, Basic -2.98 USD/shares -48%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $8,235,469 USD -8.5%
Marketable Securities, Current $12,628,970 USD -58%
Cash, Cash Equivalents, and Short-term Investments $20,900,000 USD
Other Assets, Current $19,975 USD -90%
Assets, Current $22,879,018 USD -47%
Other Assets, Noncurrent $0 USD -100%
Assets $22,879,018 USD -47%
Accounts Payable, Current $1,454,118 USD -3.8%
Employee-related Liabilities, Current $1,061,766 USD 32%
Liabilities, Current $4,656,117 USD 20%
Liabilities $4,656,117 USD 20%
Accumulated Other Comprehensive Income (Loss), Net of Tax $5,816 USD -90%
Retained Earnings (Accumulated Deficit) $97,697,851 USD -38%
Stockholders' Equity Attributable to Parent $18,222,901 USD -54%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $5,336,378 USD
Liabilities and Equity $22,879,018 USD -47%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $3,894,359 USD -174%
Net Cash Provided by (Used in) Investing Activities $5,396,577 USD
Common Stock, Shares Authorized 1,000,000,000 shares 0%
Common Stock, Shares, Issued 9,252,719 shares 6.3%
Common Stock, Par or Stated Value Per Share 0.001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,502,218 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $10,501,714 USD 65%
Deferred Tax Assets, Gross $28,207,953 USD 49%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $27,016,748 USD -66%
Deferred Tax Assets, Operating Loss Carryforwards $21,388,936 USD 105%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 30,000,000 shares
Unrecognized Tax Benefits $0 USD
Additional Paid in Capital $115,905,684 USD 5.5%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $27,687,487 USD 49%
Share-based Payment Arrangement, Expense $1,448,634 USD 3.1%
Preferred Stock, Par or Stated Value Per Share 0.001 USD/shares